John G. Ullman & Associates’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.29M Sell
12,250
-100
-0.8% -$9.31K 0.17% 100
2026
Q2
$926K Buy
12,350
+1,050
+9% +$67.4K 0.11% 106
2026
Q1
$637K Sell
11,300
-2,300
-17% -$150K 0.08% 122
2025
Q4
$1.09M Buy
13,600
+1,650
+14% +$111K 0.15% 99
2025
Q3
$582K Buy
+11,950
New +$740K 0.08% 121

Other funds holding HAE

John G. Ullman & Associates's HAE Position: Q3 2026 in Review

John G. Ullman & Associates reduced its Haemonetics (HAE) stake by 0.81% in Q3 2026, selling an estimated $9.31K and leaving 12,250 shares worth $1.29M. The position accounts for 0.17% of the portfolio, ranked #100.

John G. Ullman & Associates first reported a position in HAE in Q3 2025 and has held it in 5 quarters since. 358 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • John G. Ullman & Associates held 12,250 shares of Haemonetics worth $1.29M as of Q3 2026.
  • John G. Ullman & Associates sold 100 Haemonetics shares in Q3 2026, an estimated $9.31K.
  • Haemonetics made up 0.17% of John G. Ullman & Associates's portfolio in Q3 2026, its #100 holding.
  • John G. Ullman & Associates first reported a position in Haemonetics in Q3 2025 and has held it in 5 quarters since.
  • 358 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on John G. Ullman & Associates's 13F filing for Q3 2026, filed 4 Nov 2026.